STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMUX
  4. [Form 4/A] Immunic, Inc. Amended Insider Trading Activity

Immunic Boosts Executive Retention with Major Options Package to Chief Medical Officer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

This Form 4/A amends a previously filed Form 4 for Andreas Muehler, Chief Medical Officer of Immunic (IMUX), correcting an administrative error in reported stock option grants.

Key details of the amended filing:

  • Transaction Date: June 5, 2025
  • Grant of 598,500 stock options at exercise price of $0.7729 per share
  • Options expire on June 5, 2035
  • Vesting Schedule: 25% after first year, remaining 75% monthly over next 36 months

The amendment was necessary to correct the number of stock options granted, which was incorrectly reported in the original Form 4 filed on June 9, 2025. The options represent a significant equity compensation package for the CMO, with a ten-year exercise window.

Positive

  • Chief Medical Officer Andreas Muehler received a significant stock option grant of 598,500 shares at $0.7729 per share, representing a strong long-term alignment with shareholder interests

Negative

  • None.
Insider Muehler Andreas
Role Chief Medical Officer
Type Security Shares Price Value
Grant/Award Stock Option 598,500 $0.00 --
Holdings After Transaction: Stock Option — 598,500 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Muehler Andreas
(Last) (First) (Middle)
1200 AVENUE OF THE AMERICAS
SUITE 200
(Street)
NEW YORK CITY NY 10036
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
06/09/2025 		6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $0.7729 06/05/2025 A 598,500 (1) 06/05/2035 Common Stock 598,500 $0.00 598,500 D
Explanation of Responses:
1. 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.
Remarks:
This Form 4/A is being filed to amend the prior Form 4 filed by the Reporting Peron on June 9, 2025 to correct an administrative error that incorrectly reported the number of stock options granted.
/s/ Andreas Muehler 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many stock options were granted to IMUX's Chief Medical Officer Andreas Muehler on June 5, 2025?

Andreas Muehler was granted 598,500 stock options of IMUX on June 5, 2025, with an exercise price of $0.7729 per share.

What is the vesting schedule for IMUX CMO's June 2025 stock options?

The stock options vest over 4 years, with 25% vesting on the first anniversary of the grant date (June 5, 2026), and the remaining 75% vesting in equal monthly increments over the following 36 months.

When do Andreas Muehler's IMUX stock options expire?

The stock options granted to Andreas Muehler expire on June 5, 2035, which is 10 years from the grant date.

Why did IMUX file a Form 4/A amendment for Andreas Muehler's stock options?

IMUX filed the Form 4/A to amend the prior Form 4 filed on June 9, 2025, to correct an administrative error that incorrectly reported the number of stock options granted to Andreas Muehler.

What is the exercise price of IMUX CMO's June 2025 stock options?

The exercise price of the stock options granted to IMUX's Chief Medical Officer is $0.7729 per share.